Real-Time Quantitative RT-PCR to Detect Fusion Gene Transcripts Associated With AML

  • Rajinder Flora
  • David Grimwade
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 91)


Relapse remains a major cause of treatment failure in acute myeloid leukemia (AML); however, patients destined to relapse cannot be reliably distinguished on the basis of pretreatment characteristics. Hence, there has been considerable interest in strategies for detection of minimal residual disease (MRD) as a means of identifying patients at high risk from relapse who could benefit from additional therapy. Moreover, MRD monitoring also affords the opportunity to reveal subsets of patients at low risk of relapse who could be spared excessive therapy, thereby reducing the risk of treatment related mortality and morbidity. Previous studies have confirmed that MRD monitoring using PCR- or flow cytometric-based approaches provides key independent prognostic information in a number of subtypes of leukemia and is increasingly being used for risk stratification as a means of directing treatment approach (see refs. 1,2 for recent reviews).


Acute Myeloid Leukemia Fusion Gene Minimal Residual Disease Laminar Flow Hood Plasmid Standard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Foroni, L. and Hoffbrand, A. V., (eds.) (2002) Minimal residual disease investigation in haematological malignancies. Baillière Best Pract. Res. Clin. Haematol. 15, 1–195.Google Scholar
  2. 2.
    Szczepanski, T., Orfão, A., van der Velden, V. H. J., mnSan Miguel, J. F., and van Dongen, J. J. M. (2001) Minimal residual disease in leukaemia patients. Lancet Oncol. 2, 409–417.Google Scholar
  3. 3.
    Grimwade, D. (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Baillière Best Pract. Res. Clin. Haematol. 14, 497–529.CrossRefGoogle Scholar
  4. 4.
    Grimwade, D. (2002) The significance of minimal residual disease in patients with t(15;17). Baillière Best Pract. Res. Clin. Haematol. 15, 137–158.CrossRefGoogle Scholar
  5. 5.
    Yin, J. A. and Tobal, K. (1999) Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance. Br. J. Haematol. 106, 578–590.PubMedCrossRefGoogle Scholar
  6. 6.
    Lo Coco, F., Diverio, D., Avvisati, G., et al. (1999) Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94, 2225–2229.PubMedGoogle Scholar
  7. 7.
    Tobal, K., Newton, J., Macheta, M., et al. (2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95, 815–819.PubMedGoogle Scholar
  8. 8.
    Hochhaus, A. (2002) Minimal residual disease in chronic myeloid leukaemia patients. Baillière Best Pract. Res. Clin. Haematol. 15, 159–178.CrossRefGoogle Scholar
  9. 9.
    Cavé, H., van der {mnWerff ten Bosch}, J., Suciu, S., et al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 339, 591–598.PubMedCrossRefGoogle Scholar
  10. 10.
    Van Dongen, J. J., Seriu, T., Panzer-Grumayer, E. R., et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352, 1731–1738.PubMedCrossRefGoogle Scholar
  11. 11.
    Goulden N. J., Knechtli C. J. C., Garland R. J., et al. (1998) Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br. J. Haematol. 100, 235–244.PubMedCrossRefGoogle Scholar
  12. 12.
    Bustin, S. A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169–193.PubMedCrossRefGoogle Scholar
  13. 13.
    van der Velden, V. H. J., Hochhaus, A., Cazzaniga, et al. (2003) Detection of minimal residual disaese in hematologic malignacies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17, 1013–1034.PubMedCrossRefGoogle Scholar
  14. 14.
    Nakao, M., Janssen, J. W. G., Flohr, T., and Bartram, C. R. (2000) Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler Technology. Cancer Res. 60, 3281–3289.PubMedGoogle Scholar
  15. 15.
    Eckert, C., Landt, O., Taube, T., et al. (2000) Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 14, 316–323.PubMedCrossRefGoogle Scholar
  16. 16.
    Gabert, J., Beillard, E., van der Velden, V. H. J., et al. (2003) Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for minimal residual disease detection in leukemia patients. Leukemia (in press).Google Scholar
  17. 17.
    Beillard, E., Pallisgaard N., van der Velden, V. H. J., et al. (2003) Evaluation of candidate control genes for “real-time” quantitative reverse-transcriptase PCR analysis of fusion gene transcripts in leukemia patients—A Europe Against Cancer Program. Leukemia (in press).Google Scholar
  18. 18.
    Grimwade, D., Langabeer, S., Howe, K., and Solomon, E. (1998) RT-PCR in diagnosis and disease monitoring of acute promyelocytic leukemia (APL). Methods Mol. Biol. 89, 333–358.PubMedGoogle Scholar
  19. 19.
    van Dongen, J. J. M., Macintyre, E. A., Gabert, J. A., et al. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13, 1901–1928.PubMedCrossRefGoogle Scholar
  20. 20.
    Hokland, P. and Pallisgaard, N. (2000) Integration of molecular methods for detection of balanced translocations in the diagnosis and follow-up of patients with leukemia. Semin. Hematol. 37, 358–367.PubMedCrossRefGoogle Scholar
  21. 21.
    Pennings, J. L. A., Van de Locht, L. T. F., Jansen, J. H., Van der Reijden, B. A., De Witte, T., and Mensink, E. J. B. M. (2001) Degradable dU-based DNA template as a standard in real-time PCR quantitation. Leukemia 15, 1962–1965.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Rajinder Flora
    • 1
  • David Grimwade
    • 1
  1. 1.Division of Medical and Molecular GeneticsGuy’s, King’s, and St. Thomas’ School of MedicineLondonUK

Personalised recommendations